Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.

Tytuł:: Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Autorzy:: Pericas P; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain. .; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain. .
Mas-Lladó C; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Ramis-Barceló MF; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Valadrón I; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Noris Mora M; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Pasamar Márquez L; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
González Colino R; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Forteza Albertí JF; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Peral Disdier V; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.
Rossello X; Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain.; Grupo de investigación de Fisiopatología y Terapéutica Cardiovascular, Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain.; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Źródło:: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2021 Mar; Vol. 28 (2), pp. 167-175. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Auckland : Adis, Springer International
Original Publication: Milano : Editrice Kurtis s.r.l., c1992-
MeSH Terms:: Aminobutyrates/*therapeutic use
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
Heart Failure/*drug therapy
Neprilysin/*antagonists & inhibitors
Protease Inhibitors/*therapeutic use
Stroke Volume/*drug effects
Tetrazoles/*therapeutic use
Ventricular Function, Left/*drug effects
Aged ; Aminobutyrates/adverse effects ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Biphenyl Compounds ; Diastole ; Drug Combinations ; Echocardiography ; Female ; Heart Failure/diagnostic imaging ; Heart Failure/physiopathology ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Prospective Studies ; Protease Inhibitors/adverse effects ; Recovery of Function ; Tetrazoles/adverse effects ; Time Factors ; Treatment Outcome ; Valsartan
References:: Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam C. Heart failure around the world. Eur J Heart Fail. 2019;21:1187–96. (PMID: 10.1002/ejhf.1585)
Pellicori P, Khan MJI, Graham FJ, Cleland JGF. New perspectives and future directions in the treatment of heart failure. Heart Fail Rev. 2020;25:147–59. (PMID: 10.1007/s10741-019-09829-7)
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55. (PMID: 10.1056/NEJM199605233342101)
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35. (PMID: 10.1056/NEJM198706043162301)
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17. (PMID: 10.1056/NEJM199909023411001)
Rossello X, Ariti C, Pocock SJ, Joao PF, Girerd N, McMurray JJV, Van Veldhuisen DJ, Pitt B, Zannad F. Impact of mineralocorticoid receptor antagonist on the risk of sudden cardiac death in patients with heart failure ant left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clin Res Cardiol. 2019;108:477–86. (PMID: 10.1007/s00392-018-1378-0)
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. (PMID: 10.1056/NEJMoa1409077)
Consentino ER, Esposti DD, Miceli R, Bentivenga C, Landolfo M, Cicero AFG, Berardi E, Spinardi L, Magri G, Dugato V, Borghi C. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Curr Med Res Opin. 2019;35:9–12. (PMID: 10.1080/03007995.2019.1576481)
Moliner-Arbós C, Rivas-Lasarte M, Pamies Besora J, Fluvià-Brugues P, Solé-González E, Mirabet S, López López L, Brossa V, Pirla MJ, Mesado N, Álvarez-García J, Roig E. Sacubitril–Valsartan in real-life practice: experience in patients with advanced heart failure and systematic review. Cardiovasc Drugs Ther. 2019;33:307–14. (PMID: 10.1007/s10557-019-06858-0)
Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, Mielniczuk L. Ejection fraction improvement and reverse remodeling achieved with sacubitril/valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 2017;7:108–13. (PMID: 293489715768868)
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435. (PMID: 10.1111/1755-5922.12435)
Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD. Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1–11. (PMID: 10.1001/jama.2019.12821)
Khan Z, Gholkar G, Tolia S, Kado H, Zughaib M. Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. Int J Cardiol. 2018;271:169–73. (PMID: 10.1016/j.ijcard.2018.03.093)
Ponikowski P, Voors A, Anker S, Bueno H, Cleland JGF, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200. (PMID: 10.1093/eurheartj/ehw128)
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137-161. (PMID: 10.1161/CIR.0000000000000509)
Lang R, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39. (PMID: 10.1016/j.echo.2014.10.003)
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314. (PMID: 10.1016/j.echo.2016.01.011)
Singh A, Addetia K, Maffessanti F, Mor-Avi V, Lang RM. LA strain categorization of LV diastolic dysfunction. JACC Cardiovasc Imaging. 2017;10:735–43. (PMID: 10.1016/j.jcmg.2016.08.014)
Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019;139:1354–65. (PMID: 10.1161/CIRCULATIONAHA.118.037077)
Worley E, Rana B, Williams L, Robinson S. Left ventricular diastolic dysfunction: identifying presence by left atrial function. Echo Res Pract. 2018;5:97–104. (PMID: 10.1530/ERP-18-0013)
Muiesan ML, Paini A, Agabiti Rosei C, Bertacchini F, Stassaldi D, Salvetti M. Current pharmacological therapies in heart failure patients. High Blood Press Cardiovasc Prev. 2017;24:107–14. (PMID: 10.1007/s40292-017-0194-3)
Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133:1115–24. (PMID: 10.1161/CIRCULATIONAHA.115.018622)
Contributed Indexing:: Keywords: Diastolic function; Heart failure; Sacubitril–valsartan; Systolic function
Substance Nomenclature:: 0 (Aminobutyrates)
0 (Angiotensin II Type 1 Receptor Blockers)
0 (Biphenyl Compounds)
0 (Drug Combinations)
0 (Protease Inhibitors)
0 (Tetrazoles)
80M03YXJ7I (Valsartan)
EC 3.4.24.11 (Neprilysin)
WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
Entry Date(s):: Date Created: 20210218 Date Completed: 20210406 Latest Revision: 20211204
Update Code:: 20240105
DOI:: 10.1007/s40292-021-00437-x
PMID:: 33599965
: Czasopismo naukowe

Full Text Finder

Introduction: Sacubitril/valsartan (S-V) has been shown to reduce clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been mostly attributed to an improvement in systolic function.
Aim: This study aimed to evaluate longitudinal changes in several echocardiographic parameters of diastolic function in a cohort of patients with HFrEF receiving S-V.
Methods: Echocardiographic parameters of consecutive patients receiving S-V, such as diastolic dysfunction (DD) grade and other individual diastolic and systolic function parameters, were prospectively collected at baseline and at 6-month follow-up. New York Heart Association (NYHA) functional class was also recorded.
Results: 65 patients (73.9% males; 61.5 ± 13 years) with HFrEF in NYHA class II-IV were evaluated. There was a significant reduction in DD grade after treatment with maximal tolerated doses (p < 0.001). Patients with advanced DD showed the most significant improvements: 75% and 60% of patients with initial grade 3 and 2, respectively, had better grade after 6 months of S-V. Moreover, there was a reduction in E/e' ratio (p = 0.004), left atrial longitudinal strain (p = 0.002), and an improvement of left ventricle ejection fraction (p < 0.001) and NYHA functional class (p = 0.001). Among those subjects who improved their functional class, a higher percentage improved their DD grade (39.3%, p = 0.025) in comparison with those not improving their NYHA class (25%, p = 0.434).
Conclusions: In addition to an improvement in systolic function parameters, patients with HFrEF receiving S-V improved their diastolic function. This echocardiographic improvement is particularly relevant in those patients with better NYHA class at 6-month follow-up.

Comment in: High Blood Press Cardiovasc Prev. 2021 Jul;28(4):331-332. (PMID: 33905096)

Informacja